Context. Fatigue is a common problem in oncology patients. Less is known about decrements in energy levels and the mechanisms that underlie both fatigue and energy.
Introduction
Fatigue is the most common symptom associated with cancer and its treatments.
1 Although several studies have examined fatigue in breast cancer patients receiving chemotherapy (CTX) 2 and radiation, 3 studies on the occurrence of and predictors for fatigue after surgery are scarce. In a recent study, 4 patients with breast cancer reported relatively high levels of fatigue in the first two months after surgery followed by mild-to-moderate levels of fatigue that persisted for 12 months after surgery.
The measurement of a patient's level of energy has received little or no attention in the cancer literature. Although energy level is commonly thought of as the opposite of fatigue, evidence suggests that fatigue and energy are distinct but related concepts. 5, 6 In oncology, fatigue is defined as a distressing and persistent sense of physical, emotional, and/or cognitive tiredness or exhaustion related to cancer or its treatment that is not proportional to recent activity and interferes with usual functioning. 7 In contrast, energy is defined as an individual's potential to perform physical and mental activity. 6 In the only study that evaluated energy levels in patients with breast cancer before surgery, 8 while 32% of the women reported clinically meaningful levels of fatigue, nearly 50% of these women reported clinically meaningful decrements in energy levels. Findings from this study, 8 and a study of patients who underwent radiation and their family caregivers 9 and a study of patients with HIV disease, 10 support the hypothesis that energy is a distinct concept from fatigue.
Factors that contribute to fatigue severity are multidimensional and include numerous biopsychosocial characteristics.
11 Some of the predictors of fatigue after breast cancer surgery include higher levels of anxiety; the personality characteristic of extraversion; 12 increased fatigue prior to surgery; 13 higher levels of emotional distress, mental fatigue, and pain; 14 and depressive symptoms and receipt of CTX. 4 Recent evidence suggests that genetic mechanisms contribute to the severity of fatigue experienced by breast cancer patients. For example, in one study, 15 a number of pro-inflammatory cytokine genes were associated with fatigue. In another study, 16 polymorphisms in IL1B and IL10 were associated with fatigue in women who underwent breast cancer surgery. Polymorphisms in cytokine genes may contribute to fatigue severity through the modulation of pro-and anti-inflammatory pathways. 17, 18 Although the majority of studies on genetic associations with fatigue has focused on cytokine dysregulation, a number of additional pathways may influence fatigue and energy levels (for review, see Saligan et al. 19 ). Neurotransmitter dysregulation may play an important role in the severity of fatigue and/or changes in energy levels. The most commonly cited neurotransmitter associated with fatigue is serotonin. For example, increased serum levels of serotonin were linked to fatigue after prolonged exercise. 20 However, it is unlikely that a single neurotransmitter is responsible for the development of/or changes in fatigue and/or energy levels. Rather, it is more likely that several neurotransmitters contribute to interindividual variability in fatigue and energy. 21 Some neurotransmitter genes that were associated with fatigue and energy in a variety of populations include alterations in the dopaminergic system, specifically polymorphisms in catechol-O-methyl-transferase (COMT ), dopamine-2 receptor (DRD2), and dopamine-1 transporter (DAT1). 22 For example, in a recent study that evaluated for differences in gene expression in breast cancer patients who reported lower vs. higher levels of evening fatigue during CTX, 23 between-group differences were identified in a number of neurotransmitter pathways. However, no studies were identified that evaluated for associations between neurotransmitter genes and fatigue and energy levels in patients with breast cancer.
The present study is based on our recent work that used growth mixture modeling (GMM) to identify distinct latent classes for fatigue severity and decrements in energy levels in women (n ¼ 398) before and for six months after breast cancer surgery. 16 Fatigue and energy levels were evaluated using the Lee Fatigue Scale (LFS) . 24 In the GMM analysis for fatigue, two distinct latent classes were identified (i.e., lower fatigue [38.5%] and higher fatigue [61.5%]). At enrollment, mean fatigue scores were 1.60 and 3.90 for the lower and higher fatigue classes, respectively. In both fatigue classes, fatigue scores remained relatively constant from the preoperative assessment to six months after breast cancer surgery. In the GMM analysis for energy, two distinct latent classes were identified (i.e., higher energy [32.0%] and lower energy [68.0%]). At enrollment, mean energy scores were 5.82 and 4.35 for the higher and lower energy classes, respectively. In both energy groups, energy levels remained relatively constant from the preoperative assessment to six months after breast cancer surgery.
Given the paucity of research on the role of various neurotransmitters in the mechanism that underlie fatigue severity or decrements in energy levels in patients with breast cancer, the purpose of this study was to evaluate for associations between variations in a number of genes involved in neurotransmission, drug metabolism, and transport of molecules across cell membranes between the lower and higher fatigue latent classes and between the higher and lower energy latent classes.
Methods

Patients and Settings
The study methods are described in detail elsewhere. 8, 25, 26 In brief, patients were recruited from 2004 to 2008, from Breast Care Centers located in a Comprehensive Cancer Center, two public hospitals, and four community practices. Patients were eligible to participate if they were adult women ($18 years) who were scheduled to undergo unilateral breast cancer surgery; were able to read, write, and understand English; agreed to participate; and gave written informed consent. Patients were excluded if they were having breast cancer surgery on both breasts and/or had distant metastasis at the time of diagnosis.
Instruments
The demographic questionnaire obtained information on age, marital status, education, ethnicity, employment status, and living situation. Functional status was evaluated using the Karnofsky Performance Status (KPS) scale. 27 The number and impact of comorbid conditions was evaluated using the Selfadministered Comorbidity Questionnaire (SCQ). 28 The LFS consists of 18 items designed to assess physical fatigue and energy. 24 Each item was rated on a 0 to 10 numeric rating scale. Total fatigue and energy scores were calculated as the mean of the 13 fatigue items and the five energy items, with higher scores indicating greater fatigue severity and higher levels of energy. Patients were asked to rate each item based on how they felt ''right now.'' Cutoff scores of $ 4.4 and # 4.8 indicate clinically meaningful levels of fatigue severity and low levels of energy. 3 The LFS has well-established validity and reliability. 24, 29 Cronbach's alphas for fatigue and energy scales were 0.96 and 0.93, respectively.
Study Procedures
The study was approved by the Committee on Human Research at the University of California, San Francisco, and by the institutional review boards at each of the study sites. During the patients' preoperative visit, a clinician explained the study and determined patients' willingness to participate. The research nurse met with interested women, determined eligibility, and obtained written informed consent before surgery. After obtaining consent, patients completed the enrollment questionnaires an average of four days before surgery. Patients completed the LFS at enrollment and monthly for six months (i.e., seven assessments). Medical records were reviewed for disease and treatment information.
Genomic Analyses
Gene Selection. Thirty candidate genes involved in various aspects of neurotransmission, drug metabolism, or transport of molecules across cell membranes were evaluated (Supplementary Table 1) . Genes involved in catecholaminergic neurotransmission included alpha-1D-adrenergic receptor (ADRA1D), alpha-2A-adrenergic receptor (ADRA2A), beta-2-adrenergic receptor (ADRB2), beta-3-adrenergic receptor (ADRB3), beta adrenergic receptor kinase 2 (ADRBK2), solute-like carrier (SLC) family 6 member 2dnoradrenaline transporter (SLC6A2), SLC family 6 member 3ddopamine transporter (SLC6A3), tyrosine hydroxylase (TH ), and COMT. The gene involved in gamma-aminobutyric acid (GABA)-ergic neurotransmission was the SLC family 6 member 1dGABA transporter (SLC6A1). Genes involved in serotonergic neurotransmission included 5-hydroxytryptamine receptor (HTR) 1A (HTR1A), HTR 1B (HTR1B), HTR 2A (HTR2A), HTR 3A (HTR3A), SLC family 6 member 4dseroto-nin transporter (SLC6A4), and tryptophan hydroxylase 2 (TPH2). Genes involved in molecular transport and drug metabolism were adenosine triphosphateebinding cassette, subfamily B member 1 (ABCB1) and cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4). A number of genes involved in various aspects of neurotransmission that were evaluated included brain-derived neurotrophic factor (BDNF ), galanin (GAL), galanin receptor 1 (GALR1), galanin receptor 2 (GALR2), GTP cyclohydrolase 1 (GCH1), nitric oxide synthase 1 (NOS1), nitric oxide synthase 2 (NOS2), neuropeptide Y (NPY ), neuropeptide Y receptor 1 (NPY1R), prodynorphin (PDYN ), tachykinin precursor 1 (TAC1), and tachykinin receptor 1 (TACR1). All genes were identified according to the approved symbol stored in the Human Genome Organization Gene Nomenclature Committee database (http://www.genenames.org).
Blood Collection and Genotyping. Of the 398 patients who completed the enrollment assessment, 310 provided a blood sample from which DNA could be isolated from peripheral blood mononuclear cells (PBMCs). Genomic DNA was extracted using the PUREGene DNA Isolation System (Invitrogen, Carlsbad, CA). DNA was quantitated with a Nanodrop Spectrophotometer (ND-1000) and normalized to a concentration of 50 ng/mL (diluted in 10 mM Tris/ 1 mM EDTA). Genotyping was performed using a custom array on the Golden Gate genotyping platform (Illumina, San Diego, CA) and processed according to the standard protocol using GenomeStudio (Illumina).
Single-Nucleotide
Polymorphisms Selection. Tagging single-nucleotide polymorphisms (SNPs) and literature-driven SNPs were selected for analysis. Tagging SNPs were required to be common (defined as having a minor allele frequency of $ 0.05) in public databases. To ensure robust genetic association analyses, quality control filtering of SNPs was performed. SNPs with call rates of less than 95% or HardyWeinberg P-values of < 0.001 were excluded. A total of 249 SNPs among the 30 candidate genes passed all the quality control filters and were included in the genetic association analyses (Supplementary Table 1) .
Localization of SNPs on the human genome was performed using the GRCh38 human reference assembly. Regional annotations were identified using the University of California Santa Cruz Human Genome Browser GRCh37/hg19 (http://genome. ucsc.edu/cgi-bin/hgTracks?db¼hg38). Potential regulatory involvement of SNPs was investigated using ENCODE.
30
Genotyping the Serotonin-Linked Polymorphic Region of SLC6A4
The serotonin transporter-linked polymorphic region (5-HTTLPR) occurs in the promoter region of the SLC6A4 gene. 5-HTTLPR occurs primarily as either a shorter (S, i.e., 14 repeats of 23 nucleotides) or longer (L, i.e., 16 repeats) sequence.
31 5-HTT rs25531 is an SNP, which is present in either a common (A) or rare (G) variant and is located immediately upstream of the 5-HTTLPR.
32,33
The 5-HTTLPR/rs25531 haplotype (i.e., 5-HTTLPR triallelic polymorphism) is known to influence SLC6A4 expression levels. In vitro studies of the L allele suggest that the L A allele exhibits higher 5-HTT transcription and that the L G allele is more similar in function to the S allele. 32, 34 In this study, the L A allele was used as the reference allele. The 5-HTTLPR polymorphism was measured using polymerase chain reaction followed by resolution of polymerase chain reaction products by gel electrophoresis. 35 The rs25531 genotype was obtained by DNA cycle sequencing.
Statistical Analyses for the Phenotypic Data
Data were analyzed using SPSS, version 22 (IBM Corp, Armonk, NY), 36 and STATA, version 13 (StataCorp LP, College Station, TX). 37 As described previously, 16 unconditional GMM with robust maximum likelihood estimation was carried out to identify latent classes with distinct fatigue and energy trajectories using Mplus, version 5.21.
38e40 Descriptive statistics and frequency distributions were generated for sample characteristics. Independent sample t-tests, MannWhitney U tests, and chi-squared analyses were used to evaluate for differences in demographic and clinical characteristics between the two latent classes for fatigue and energy. A P-value of < 0.05 was considered statistically significant.
Statistical Analyses for the Genetic Data
The genomic analyses are described in detail elsewhere. 16 In brief, allele and genotype frequencies were determined by gene counting. Hardy-Weinberg equilibrium was assessed by the chi-square or Fisher exact tests. Measures of linkage disequilibrium (i.e., D 0 and r 2 ) were computed using Haploview 4.2. Haplotypes were constructed using PHASE, version 2.1.
41
Only inferred haplotypes that occurred with a frequency estimate of $ 15% were included in the association analyses, assuming a dosage model.
Ancestry informative markers were used to minimize confounding because of population stratification.
42e44 Homogeneity in ancestry among patients was verified by principal component analysis, 45 using HelixTree (GoldenHelix, Bozeman, MT). The first three PCs were used in all the logistic regression models.
For association tests, three genetic models were assessed for each SNP: additive, dominant, and recessive. The genetic model that best fit the data, by maximizing the significance of the P-value, was selected for each SNP. Logistic regression analysis, that controlled for significant covariates, and genomic estimates of (i.e., ancestry informative markers) and self-reported race/ethnicity, was used to evaluate the associations between genotype and higher fatigue and lower energy class memberships. Only those genetic associations identified as significant from the bivariate analyses were evaluated in the multivariate analyses. A backward stepwise approach was used to create a parsimonious model. Except for race/ ethnicity, only predictors with a P-value of < 0.05 were retained in the final model.
As was done in our previous studies, 9,46e50 based on the recommendations in the literature, 51, 52 and the implementation of rigorous quality controls for genomic data, the nonindependence of SNPs/haplotypes in linkage disequilibrium, and the exploratory nature of the analyses, adjustments were not made for multiple testing. In addition, significant SNPs identified in the bivariate analyses were evaluated further using logistic regression analyses that controlled for differences in phenotypic characteristics, potential confounding because of population stratification, and variations in other SNPs/haplotypes within the same gene. Only those SNPs that remained significant were included in the final presentation of the results. Therefore, the significant independent associations reported are unlikely to be due solely to chance. Unadjusted associations, for all the SNPs evaluated, are found in Supplementary Table 1 , to allow for subsequent comparisons and meta-analyses.
Results
Differences in Demographic and Clinical Characteristics Between the Fatigue Classes
Differences between the two fatigue classes are listed in Table 1 . Patients in the higher fatigue class were significantly younger, had more years of education, a lower KPS score, a higher SCQ score, a higher number of lymph nodes removed, and a higher fatigue severity score at enrollment. A larger percentage of patients in the higher fatigue class had received neoadjuvant CTX and had received CTX during the first six months after breast cancer surgery. SNP in GCH1, five SNPs and two haplotypes in NOS1, one SNP and one haplotype in NPY1R, one SNP and one haplotype in SLC6A1, two SNPs and one haplotype in SLC6A2, one SNP in SLC6A3, and two SNPs and one haplotype in TAC1 and in the 5HTTLPR þ rs25521 haplotype in the SLC6A4 gene.
Regression Analyses for Fatigue
In these regression analyses that included genomic estimates of and self-reported race/ethnicity, the only phenotypic characteristics that remained significant in the multivariate model were age, KPS score, SCQ score, and receipt of CTX within six months after breast cancer surgery. Eleven gene loci remained significantly associated with fatigue class membership in the regression analyses (Table 2) .
For ADRB2 rs1042718, carrying two doses of the rare A allele was associated with a 87% lower odds of belonging to the higher fatigue class (Fig. 1a) . For BDNF rs6265, carrying one or two doses of the rare A allele was associated with a 50% lower odds of belonging to the higher fatigue class (Fig. 1b) . For COMT rs9332377, carrying one or two doses of the rare C allele was associated with a 52% lower odds of belonging to the higher fatigue class (Fig. 1c) . For CYP3A4 rs4646437, carrying one or two doses of the rare T allele was associated with a 52% lower odds of belonging to the higher fatigue class (Fig. 1d) . For GALR1 rs949060, carrying two doses of the rare C allele was associated with a 2.46-fold higher odds of belonging to the higher fatigue class (Fig. 1e) . For GCH1 rs3783642, carrying one or two doses of the rare C allele was associated with a 53% lower odds of belonging to the higher fatigue class (Fig. 1f) .
For NOS1, two SNPs were associated with membership in the higher fatigue class. In the regression analysis, including both SNPs, for NOS1 rs9658498, carrying two doses of the rare C allele was associated with a 55% lower odds of belonging to the higher fatigue class (Fig. 2a) . In the same regression analysis, for NOS1 rs2293052, carrying two doses of the rare T allele was associated with a 4.58-fold higher odds of belonging to the higher fatigue class (Fig. 2b) . For NPY1R Haplotype A04 (HapA04), that is composed of alleles at two SNPs (i.e., rs9764 [common T allele] and rs7687423 [common G allele] ), each additional dose of NPY1R HapA04 was associated with a 1.77-fold higher odds of belonging to the higher fatigue class (Fig. 3) . For SLC6A2 rs17841327, carrying two doses of the rare A allele was associated with a 10.31-fold higher odds of belonging to the higher fatigue class (Fig. 2c) . For the 5-HTTLPR þ rs25531 polymorphism in SLC6A4, carrying one or two doses of the L A allele was associated with a 47% lower odds of belonging to the higher fatigue class (Fig. 2d ).
Differences in Demographic and Clinical Characteristics Between the Energy Classes
Differences between the two energy classes are listed in Table 3 . Patients in the lower energy class had a lower KPS score, a higher SCQ score, and a lower mean energy score at enrollment. In addition, a higher percentage of patients with more advanced disease were in the lower energy class.
Candidate Gene Analyses for Energy
Genotype distributions differed between the higher energy and lower energy classes for: one SNP in COMT, two SNPs in HTR2A, one SNP in NOS1, one SNP in NOS2A, four SNPs and three haplotypes in SLC6A1, four SNPs in SLC6A2, one SNP in SLC6A3, three SNPs and one haplotype in SLC6A4, one SNP in TAC1, and one SNP in TACR1.
Regression Analyses for Energy
In these regression analyses that included genomic estimates of and self-reported race/ethnicity, the phenotypic characteristics that remained significant in the multivariate model were KPS score and receipt of CTX within six months after breast cancer surgery. Seven gene loci remained significantly associated with energy class membership in the multivariate logistic regression analyses (Table 4) .
For NOS1 rs471871, carrying two doses of the rare T allele was associated with a 72% lower odds of belonging to the lower energy class (Fig. 4a ). For SLC6A1, one SNP and one haplotype were associated with membership in the lower energy class. For SLC6A1 rs2675163, carrying one or two doses of the rare C allele was associated with a 1.85-fold higher odds of belonging to the lower energy class (Fig. 4b ). In the same regression analysis, for SLC6A1 HapD01, that is composed of alleles at three SNPs (i.e., rs10514669 [common C allele], rs2697138 [common C allele] , and rs1062246 [common A allele]), each additional dose of SLC6A1 HapD01 was associated with a 40% lower odds of belonging to the lower energy class (Fig. 5) . For SLC6A2 rs36027, each additional dose of the rare G allele was associated with a 41% lower odds of belonging to the lower energy class (Fig. 4c) . For SLC6A3 rs37022, carrying two doses of the rare A allele was associated with a 9.75-fold higher odds of belonging to the lower energy class (Fig. 4d) . For SLC6A4 rs2020942, carrying two doses of the rare A allele was associated with a 64% lower odds of belonging to the lower energy class (Fig. 4e) . For TAC1 rs2072100, carrying two doses of the rare G allele was associated with a 2.11-fold higher odds of belonging to the lower energy class (Fig. 4f ).
Discussion
A discussion of the differences in phenotypic characteristics between the fatigue latent classes, and between the energy latent classes, is found in our recent article. 16 This discussion is focused on the genotypic findings.
Fatigue Polymorphisms
The ADRB2 receptor is part of the G-proteine coupled receptor family that influences sympathetic nervous system responses and plays a role in the regulation of lipid metabolism. Polymorphisms in ADRB2 are associated with bronchodilation, insulin secretion, gluconeogenesis, and glycogenolysis in skeletal muscle and also increased cardiac output, arterial dilation, and lipolysis.
53 Sarpeshkar and Bentley 53 hypothesized that alterations in this gene may be responsible for enhanced aerobic capacity and delayed exercise-induced fatigue. In addition, ADRB2 receptor stimulation inhibits production of type 1 proinflammatory cytokines, 54 and underexpression of ADRB2 receptors is associated with chronic fatigue syndrome.
55
In our study, patients who were homozygous for the rare A allele for ADRB2 rs1042718 had a 87% lower odds of belonging to the higher fatigue class. Polymorphisms in ADRB2 rs1042718 produce a silent mutation. Although no studies were identified that evaluated associations between this SNP and fatigue, significant associations were found between rs1042718 and enhanced longevity 56 and negative emotions. 57 In the negative emotions study, 57 individuals who were heterozygous or homozygous for the rare allele in rs1042718 were less likely to report feelings of uselessness, loneliness, and anxiety. Given that previous studies of oncology patients found associations between higher levels of psychological distress and fatigue, 58e60 our findings are consistent with those reported by Zheng et al.
57
COMT is a key enzyme responsible for the metabolism and inactivation of dopamine, norepinephrine, and epinephrine. 61 Alterations in the COMT gene were associated with fatigue and pain in breast cancer patients through interactions with two stress pathways (i.e., hypothalamic-pituitary-adrenal axis, the sympathetic nervous system).
61e63 In our study, patients who were heterozygous or homozygous for the rare C allele for COMT rs9332377 had a 52% lower odds of belonging to the higher fatigue class. This intronic SNP is located near the 3 0 untranslated region of the COMT gene. Although this location suggests that this polymorphism has a regulatory function and may affect COMT expression, 64 we found no support for nearby regulatory regions when the ENCODE data were reviewed. Only three studies have reported significant associations between COMT rs9332377 and clinical phenotypes (i.e., hearing loss, 65 suicidal ideation, 66 nicotine dependence 64 ). No studies have evaluated for associations between COMT rs9332377 and fatigue. However, in the study of suicidal ideation, 66 individuals who were homozygous for the rare C allele of COMT rs9332377 reported lower irritability scores on the Questionnaire for Measuring Factors of Aggression. This finding supports our association between rs9332377 and decreased fatigue when one considers COMT's role in the manifestation of emotions, a possible marker for chronic fatigue syndrome.
67
BDNF is a neural growth factor found throughout the central nervous system (CNS). BDNF is associated with overall brain health because it plays a role in the promotion of neurogenesis, neuroprotection, mental performance, and cognitive function. BDNF rs6265 is a missense mutation that results in a nonsynonymous conservative change in the amino acid sequence from valine (Val) to methionine (Met). In two studies, 71,72 decreases in serum BDNF levels were associated with the Met allele. In our study, being heterozygous or homozygous for the rare allele was associated with a reduction in the odds of belonging to the higher fatigue class. One might hypothesize that lower levels of BDNF would be associated with membership in the higher fatigue class given that lower levels of BDNF were associated with depression 71 and chronic fatigue syndrome. 70 However, findings regarding changes in serum levels of BDNF associated with the Met allele are inconsistent. 73 In addition, the effect of the Met allele on BDNF levels in the brain, where it may play a greater role in the perception of fatigue, remains unknown. The CYP3A4 gene is a part of the cytochrome P450 superfamily. Cytochrome P450 enzymes are responsible for catalyzing multiple reactions involved in lipid synthesis and drug metabolism. These enzymes are responsible for the metabolism of approximately one third of anticancer drugs. 74 The rs4646437 SNP is located in intron 7 of CYP3A4. Although no studies evaluated for associations between CYP3A4 rs4646437 and fatigue, in one study, 75 an association was found between CYP3A4 rs4646437 and in vitro CYP3A expression and activity. In this study, women who carried the rare T allele of rs4646437 had higher expression and activity of the CYP3A4 enzyme. Considering CYP3A4's role in metabolizing anticancer drugs, one can hypothesize that women who are able to more effectively metabolize CTX would be less likely to experience higher levels of fatigue. This hypothesis is supported by our findings that being heterozygous or homozygous for rare T allele for rs4646437 was associated with a 52% lower odds of belonging to the higher fatigue class.
Galanin, a neuropeptide found throughout the CNS, has an inhibitory effect on multiple neurotransmitters. 76 Polymorphisms in the galanin gene are associated with eating disorders, 77 cancer, 78 Alzheimer's disease, 79,80 depression, and anxiety. 76 Within the CNS, the functional effects of galanin are mediated by three G-proteinecoupled receptor subtypes, including GALR1. The GAL1 receptor has an inhibitory effect on adenylate cyclase through coupling with the G proteins Gi/Go. This inhibition affects adenosine triphosphate metabolism and plays an important role in cellular energy pathways. 80 Of note, Staines 81 hypothesized that dysfunctions in G proteinecoupled receptors (e.g., GALR1) contribute to the development of fatigue. In our study, patients who are homozygous for the rare C allele for GALR1 rs949060 had a 2.46-fold higher odds of belonging to the higher fatigue class. GALR1 rs949060 is located on chromosome 18, approximately 3 kilobases upstream of the GALR1 gene in the promoter region. However, no nearby regulatory element was identified in the ENCODE data.
GCH1 is the rate-limiting enzyme involved in the synthesis of tetrahydrobiopterin (BH4). BH4 plays a role in nitric oxide (NO) production and hydroxylation of aromatic amino acids. Polymorphisms in GCH1 are associated with pain, 82 altered cognitive performance, 83 and dopa-responsive dystonia. 84 In our study, being heterozygous or homozygous for the rare C allele for GCH1 rs3783642 was associated with a 53% lower odds of belonging to the higher fatigue class. Although no studies reported on GCH1 rs3783642, one study 85 found a protective association 0 value (range: 0e1, inclusive) was rendered in color, with the darker red diamond representing D 0 value approaching 1.0. When the r 2 (range 0e100, inclusive) is not equal to 0 or 100, it is provided in a given diamond. The two-SNP haplotype associated with fatigue is composed of rs9764 and rs7687423. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.) between other polymorphisms in GCH1 and fibromyalgia syndrome. This locus resides in putative CCCTC-binding factor (CTCF) and RAD22 transcription factorebinding sites that suggests a possible role in the regulation of GCH1.
NPY1R is part of a family of G proteinecoupled receptors that binds NPY. NPY acts in both the CNS and peripheral nervous system. Peripherally, NPY is a neurotransmitter that is released from sympathetic nerve endings. Centrally, NPY acts on receptors present in those areas of the brain that are involved with emotion.
86 NPY is involved in sleep regulation, anxiety, memory, pain, and energy homeostasis. 87, 88 Alterations in NPY are implicated in chronic fatigue syndrome 86 and depression. 89 Alterations in NPY signaling through variations in NPY1R may have an effect on any of the aforementioned processes, including fatigue.
In our study, each additional dose of NPY1R HapA04 was associated with a 1.77-fold higher odds of belonging to the higher fatigue class. HapA04 comprised a 3 0 untranslated region SNP (rs9764) and one intronic SNP (rs7687423). Although no studies were identified that reported on NPYR1 HapA04, polymorphisms in rs9764 and rs7687423 were associated with nicotine 90 and methamphetamine 91 dependence, respectively. No studies were identified that reported on associations with either SNP and fatigue.
Energy Polymorphisms
The SLC6A1 gene encodes for one of the four GABA transporters found in the brain. The role of this transporter is to remove GABA from the synaptic cleft that decreases extracellular levels of GABA. The inhibitory neurotransmitter GABA is important for normal brain function. Based on studies of knockout mice, 92 deficiencies in SLC6A1 were associated with depression, reduced aggression, and reduced anxiety. Furthermore, an association was found between polymorphisms in SLC6A1 and anxiety disorders. 93 In a genome-wide association study, 94 an SNP in SLC6A1 was associated with symptoms of inattention and hyperactivity in attention-deficit/hyperactivity disorder (ADHD). In our study, one SNP and one haplotype in the SLC6A1 gene were associated with membership in the lower energy class. Being heterozygous or homozygous for the rare C allele of SLC6A1 rs2675163 was associated with a 1.85-fold higher odds of belonging to the lower energy class, whereas each additional dose of SLC6A1 HapD01, that is composed of alleles at three SNPs (i.e., rs10514669, rs2697138, and rs1062246), was associated with a 40% lower odds of belonging to the lower energy class. No studies were identified that reported on polymorphisms in any of the SLC6A1 SNPs and energy.
The SLC6A3 gene encodes for a dopamine transporter. The dopamine transporter protein is responsible for re-uptake of dopamine from the synaptic cleft that results in decreased extracellular levels of dopamine. 95 Decreased levels of dopamine are hypothesized to play a role in the development of central fatigue because of dopamine's known effects on initiation of movement.
96 Therefore, alterations in dopaminergic circuits, including its transport receptors, may affect an individual's energy level and fatigue.
Although the majority of the literature on polymorphisms in the SLC6A3 gene has focused on ADHD, 97,98 associations were found between dopaminergic polymorphisms and fatigue 22 and decreases in mental energy and sustained attention. 99 In our study, being homozygous for the rare A allele of SLC6A3 rs37022 was associated with a 9.75-fold higher odds of belonging to the lower energy class. No studies were identified that reported on polymorphisms in this SNP.
The TAC1 gene encodes for a group of tachykinin peptide hormones (e.g., Substance P) that function as neurotransmitters. Substance P is implicated in fibromyalgia syndrome 100 and with fatigue and other negative mood states.
101 Therefore, polymorphisms in tachykinin pathway genes may have an effect on fatigue and energy levels. In our study, being homozygous for the rare G allele of TAC1 rs2072100 was associated with a 2.11-fold higher odds of belonging to the lower energy class. Although the rs2072100 polymorphism was linked with increased risk for colorectal cancer 102 and susceptibility to multiple sclerosis, 103 no studies were identified that reported on associations with energy. Multiple logistic regression analyses of candidate gene associations with higher energy vs. lower energy classes (n ¼ 301). For each model, the first three principal components identified from the analysis of ancestry informative markers, as well as self-reported race/ethnicity, were retained in all models to adjust for potential confounding due to race/ethnicity. For the regression analyses, predictors evaluated in each model included genotype (NOS1 rs471871 genotype: AA þ AT vs. TT; SLC6A1 rs2675163 genotype: TT vs. TC þ CC; SLC6A1 HapD01 haplotype: composed of the rs10514669 common C allele, the rs2697138 common C allele, and the rs1062246 common A allele; SLC6A2 rs36027 genotype: AA vs. AG vs. GG; SLC6A3 rs37022 genotype: TT þ TA vs. AA; SLC6A4 rs2020942 genotype: GG þ GA vs. AA; TAC1 rs2072100 genotype: AA þ AG vs. GG), functional status (KPS score in 10-unit increments), and receipt of chemotherapy within six months after surgery.
Fatigue and Energy Polymorphisms
Three genes (i.e., NOS1, SLC6A2, and SL6A4) were associated with latent class membership for both fatigue and energy. NOS1 is part of a group of NOS responsible for the synthesis of NO. NO mediates vasodilation, neural regulation of skeletal muscle, and neurotransmission.
104 Elevated NO levels are implicated in chronic fatigue syndrome, 105 fatigue in muscular dystrophies, 106,107 and fatigue in postradiation syndrome.
108 Although no studies were identified on associations between NOS polymorphisms and fatigue, other studies found associations between polymorphisms in the NOS1 gene and depression 109 and anxiety.
110
In our study, two SNPs in the NOS1 gene were associated with membership in the higher fatigue class. Being homozygous for the rare C allele of rs9658498 was associated with a 55% lower odds of belonging to the higher fatigue class, whereas carrying two doses of the rare T allele of rs2293052 was associated with a 4.58-fold higher odds of belonging to the higher fatigue class. No studies were identified that reported on NOS1 rs9658498. However, an association was found between rs2293052 and Parkinson's disease (PD).
111 These results support our findings of an association between this SNP and increased fatigue because similar to the aforementioned fatigue syndromes, PD is associated with increased NO levels.
112
In addition, fatigue is a common symptom associated with PD 113 and may share similar susceptibility gene polymorphisms. A different SNP in the NOS1 gene was associated with energy levels. Being homozygous for the rare T allele of rs471871 was associated with a 72% lower odds of belonging to the lower energy class. No studies were identified that reported on NOS1 rs471871.
The SLCA2 gene encodes for the norepinephrine transporter (NET) protein. The NET found at noradrenergic synapses is responsible for the removal of NE from the synaptic cleft and plays a major role in NE homeostasis.
114 Impairments in the NET protein may contribute to the development of fatigue.
115 Mutations in the SLCA2 gene are associated with orthostatic intolerance, a syndrome that includes fatigue as a significant symptom. 114, 116 In addition, polymorphisms in the SLCA2 gene were associated with major depression, a condition that includes fatigue as a major symptom.
117 In our study, being homozygous for the rare A allele of SLC6A2 rs17841327 was associated with a 10.31-fold higher odds of belonging to the higher fatigue group. In addition, a different SNP in the SLC6A2 gene was associated with energy levels. Each additional dose of the rare G allele of SLC6A2 rs36027 was associated with a 41% higher odds of belonging to the lower energy class. No studies were identified that reported on either SLC6A2 SNP. The SLC6A4 gene encodes for a membrane protein that is responsible for re-uptake of serotonin from the synaptic cleft. The serotonergic neurotransmitter system is hypothesized to play a role in cancer-related fatigue. 118, 119 Serotonin is involved in various human behaviors including sleep, mood, appetite, memory, and learning. Increased levels of serotonin in the brain are hypothesized to contribute to fatigue through its interaction with the hypothalamicpituitary-adrenal axis leading to a sensation of reduced potential to perform physical activity.
118 Yamamoto et al. 120 demonstrated a reduced density of serotonin transporters in the rostral subdivision of the anterior cingulate of patients with chronic fatigue syndrome. In addition, an association was found between polymorphisms in the promoter of the SLC6A4 gene and chronic fatigue syndrome.
121
In our study, being homozygous for the rare A allele of SLC6A4 rs2020942 was associated with a 64% lower odds of belonging to the lower energy class. In addition, carrying one or two doses of the L A allele for the 5-HTTLPR þ rs25531 polymorphism in SLC6A4 was associated with a 47% decrease in the odds of belonging to the higher fatigue class. Although rs2020942 was linked with obsessive-compulsive symptoms 122 and risk for nonsyndromic cleft lip with or without cleft palate, 123 no studies have reported on associations between SLC6A4 rs2020942 and energy level.
Although the functional consequences of SLC6A4 rs2020942 are not known, a considerable amount of research has evaluated the functional consequences of the A > G polymorphism (rs25531) within the L allele of 5-HTTLPR. In this triallelic polymorphism (i.e., S, L A , and L G ), nearly equivalent expression of the serotonin transporter is observed with the S and L G alleles and increased transcriptional activity is observed with the L A allele. 32, 34 In addition, other studies found that being homozygous for the L A allele was associated with increased serotonin transporter binding. 124, 125 Because the serotonin transporter modulates the concentration of serotonin at the synaptic cleft, an increase in the transcription of the transporter would decrease the amount of serotonin at the synaptic cleft. In a number of studies, is not equal to 0 or 100, it is provided in a given diamond. The three-SNP haplotype associated with energy is composed of rs10514669, rs2697138, and rs1062246. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.) individuals who possessed one or two doses of the lowactivity alleles (S or L G ) were more likely to develop behavioral disorders (e.g., depression) when they experienced stressful life events. 126, 127 Our findings are consistent with these observations in that patients who carried one or two doses of the L A allele were less likely to be in the higher fatigue class. One can hypothesize that patients with the L A allele have increased transcription of the serotonin transporter that would decrease the concentration of serotonin at the synaptic cleft. The decreased concentration of serotonin would result in decreased levels of fatigue.
Conclusions
Several limitations must be acknowledged. Although our sample size was sufficient, additional studies with independent samples are needed to confirm the latent classes and the genetic associations. To increase the generalizability of these results, women were recruited from seven different centers and approximately 30% of the patients were ethnic minorities. However, the single diagnosis of breast cancer limits the generalizability of the findings to other cancer diagnoses. Finally, recent studies suggest that diurnal variations in fatigue and energy levels constitute distinct symptom phenotypes.
9,128,129 Future studies need to evaluate for differences in the levels of morning and evening fatigue and decrements in energy levels in women after breast cancer surgery.
The molecular findings from this study support the hypothesis that fatigue and energy are distinct, yet related symptoms. Only three of the 13 genes identified in this study were associated with membership in both the fatigue and energy latent classes. Additional support for this hypothesis comes from recent studies that explored the concepts of fatigue and energy in patients with cancer and their family caregivers 9,46 and in women with HIV.
130 Lerdal et al. 130 concluded that fatigue and energy are distinct constructs and should not be used interchangeably, neither clinically nor in research. Additional studies are needed to determine which common and distinct phenotypic and molecular characteristics are associated with increased fatigue severity and decrements in energy. Findings from these types of studies will provide insights into the mechanisms that underlie one or both of these symptoms and facilitate the development and testing of interventions to decrease fatigue and/or increase energy levels of patients undergoing cancer treatment.
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